SPDR S&P Biotech ETF Sees Significant Week-over-Week Outflow

Today, a notable change has emerged in the SPDR S&P Biotech ETF (Symbol: XBI), which experienced an approximate outflow of $288.7 million. This represents a 5.9% decrease in shares outstanding, dropping from 62,450,000 to 58,750,000 in just one week. Among XBI’s largest underlying components, trading activity shows EXACT Sciences Corp. (Symbol: EXAS) dipping about 0.4%, Alnylam Pharmaceuticals Inc. (Symbol: ALNY) down roughly 0.9%, and Natera Inc. (Symbol: NTRA) declining by about 6.1%. For a full listing of holdings, visit the XBI Holdings page.

The chart below illustrates the one-year price performance of XBI, compared to its 200-day moving average:

Looking at the data, XBI’s 52-week low stands at $66.66 per share, while its 52-week high is $105.47. Currently, the last trade occurred at $78.34. Assessing the most recent share price against the 200-day moving average can provide valuable insights into market trends.

Exchange-traded funds (ETFs) function similarly to stocks. Instead of “shares,” investors trade “units.” These units can be exchanged just like stocks, but they can also be created or destroyed to meet investor demand. Each week, we track changes in shares outstanding for ETFs to identify those experiencing significant inflows (indicating new units created) or outflows (indicating old units destroyed). As new units are formed, the ETF must purchase the underlying holdings, while unit destruction necessitates selling those holdings. Consequently, large flows can impact the individual components within the ETFs.

Click here to find out which other ETFs have experienced notable outflows.

Also see:

• Cheap Industrials Shares
• BTZ Average Annual Return
• Cintas MACD

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.